![]() No In-House Pharmacy: Hospital covered entities that do not have an in-house pharmacy may designate a single contract pharmacy location to continue to receive and dispense Boehringer products purchased at 340B prices.Boehringer will recognize the following exemptions from its new restrictive contract pharmacy policy: The list of applicable NDCs can be found here. Boehringer’s policy applies to all of its products except those distributed through specialty pharmacies (OFEV, Gilotrif, and Praxbind). notified covered entities that it will no longer honor all 340B contract pharmacy arrangements, effective August 1, 2021. By letter dated June 30, 2021, drug manufacturer Boehringer Ingelheim Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |